Novartis Consultancy Meeting: Let’s be CLEAR on dose individualization: who, when & why

The Skin-pact Factor: scoring pre- & post-procedure care to enhance patient outcomes

Breakfast & Visit Sponsors

Deucravacitinib Open Session: PsO Who Are You?

Learning Objectives:

1. Differentiate TYK2 inhibitors from JAK inhibitors
2. Identify patients with moderate-to-severe psoriasis who are candidates for oral TYK2 inhibitors based on their disease characteristics and medical history
3. Apply practical skills to managing patients on TYK2 inhibitors

Summary:
PsO Who Are You is the extraordinary dermatology conference challenge that provides compelling education for all dermatologists!
THE OBJECT OF THE GAME is to discover the answer to three questions related to the use of existing and emerging oral therapies:
WHO are the patients using oral systemic therapies?
WHAT is their medical and treatment history prior to starting an oral therapy?
WHY is an oral therapeutic an appropriate option for those patients?
THE GAME BOARD features three stellar dermatologists: Dr. David Adam, Dr. Perla Lansang, and Dr. Julien Ringuet. Of the many possible patient scenarios, each opponent will present one character who is eligible for advanced oral therapies.
THE GAME PLAY will begin with each opponent taking turns posing questions on medical history and treatment considerations in order to reveal the details of the patient case.
THE GAME ENDS when one opponent correctly guess the patient description based on the clues given throughout the presentation.
Three dermatologists, three patient profiles. Let the game begin!

Skin Health and Oat Therapy

This session will highlight the history of oat, the data supporting the mechanism of action of oat in emollients and the clinical efficacy and safety of its use in atopic dermatitis and other various skin conditions and populations.

Learning Objectives:

1. Identify the components and the multifaceted benefits of colloidal oatmeal and its effect on the moisture barrier.
2. Recognize the clinical research highlighting the benefits of colloidal oatmeal in various skin conditions.

Let’s talk GPP!

In the broad category of psoriasis lies many diseases, including the broadly known and prevalent plaque psoriasis, as well as the far less common, and rare, conditions such as guttate, inverse, erythrodermic and pustular psoriasis. Despite sharing the term psoriasis, generalized pustular psoriasis (GPP) is a distinct condition whose disease pathway is different than the far more common plaque psoriasis. This open session will serve to provide a comprehensive review of GPP, including disease mechanisms and patient prevalence/predispositions. The conversation will then dive into the burden of disease and truly call to light the unmet needs that currently exists with patients suffering with GPP. Those in attendance will gain a better understanding of this rare disease.

Learning Objectives

1. Increase awareness of generalized pustular psoriasis (GPP) as a different and distinct condition from plaque psoriasis
2. Raise awareness and highlight the burden of disease on patients with GPP
   

Advancing Standard of Care in Vitiligo and Atopic Dermatitis

CeraVe Advisory Board

Sun Pharma Acne National Advisory Board

Lunch Break & Visit Sponsors

Master the New JAK Inhibitors for Moderate to Severe Atopic Dermatitis

Learning Objectives:

1. Review the evidence supporting the use of JAK inhibitors in patients with moderate to severe atopic dermatitis
2. Define the role of JAK inhibitors to address unmet needs in the treatment of moderate to severe atopic dermatitis
3. Gain knowledge on the use of JAK inhibitors through tips and frequently asked questions (FAQs)

Antioxidants for All – all skin types and all skin tones

Vitamin C (L-ascorbic acid), in synergy with other combination antioxidants, have been shown to prevent skin damage from UV and environmental aggressors in the last 3 decades. This is achieved due to its precise formulation that maximizes its absorption and has been shown to prevent skin damage from UV and environmental aggressors in the last 3 decades. Is there is value to offering different combinations of Vitamin C-containing antioxidants for different skin types and indications? What can be expected for the range of clinical performance of these antioxidants on different Fitzpatrick skin types? A comprehensive review of the gold standard in antioxidant science, plus new diverse and inclusive clinical data, will be presented.

The case at hand: the chronic hand eczema landscape in 2022

Chronic hand eczema can have a severe impact on quality of life. Although there has been a paucity of approved therapies focused on this condition, there have recent updates to international guidelines and there are a variety of ongoing clinical development programs investigating new treatments. This session will review disease background and burden, the latest guideline updates, and briefly discuss emerging therapies to ensure attendees have the most current information on chronic hand eczema management.

Objectives: 

1. Review the definition, incidence, and disease burden of chronic hand eczema, highlighting the impact on both patients and to society
2. Describe the latest guideline updates related to the prevention and management of chronic hand eczema
3. Discuss treatment options and the potential future treatment landscape in light of currently available data
   

Overview of companies leading Chinese development of medical skin therapies

There has been a dramatic rise in high quality dermatologic scientific research publications originating in China in the past two decades, although this upward migration in knowledge creation has not been translated into therapeutic innovations. However, this is beginning to change. A number of Chinese pharmaceutical companies are making significant progresses in dermatotherapeutics research, and in some cases playing a pioneering role in the world. In this presentation, some of these progresses are described, including how Canada has contributed in, and benefited from, the accelerating skin therapeutics research in China.

Questions & Answers

Reception

Arcutis Working Group

LEO Adtralza Advisory Board

Breakfast & Visit Sponsors

SM Lectureship: Implications of Genomic Medicine for Dermatology

Professor Whittaker's talk will cover (i) an introduction to the UK strategy for embedding genomic medicine in clinical practice, (ii) specific examples for rare dermatologic disease and skin cancers such as melanoma and cutaneous lymphoma and (iii) future developments such as for common polygenic skin diseases.

Ichthyosis - New Therapeutic Targets

Questions & Answers

Pso Let’s Talk: “The Trouble with Topicals"

Chronic plaque psoriasis (PsO) is an auto-immune mediated inflammatory skin diseases that varies in severity affecting over 1 million people in Canada.1 The majority of patients present with mild to moderate disease as determined by objective measures used by clinicians, but it is increasingly recognized, disease severity experienced by the patient is more than just a body surface area or PASI score calculation as evidenced by decreased quality of life and higher risks for depression, anxiety and suicide.1,2,3 Although topical corticosteroids (TCSs) remain the foundation of treatment and are used across the spectrum of plaque PsO, there has been a paucity of clinical innovation in comparison to the advances in biologic therapies made in the past decade.3,4

Despite good treatment responses with TCSs, they can be limited for long-term use due to local (e.g., stria, skin atrophy, and telangiectasia) or systemic (e.g., hypothalamic-pituitary-adrenal [HPA] axis suppression) adverse events (AEs).5 Topical retinoids and vitamin D analogs, originally introduced in the latter part of the 20th century, have their own troublesome AEs with skin irritation (e.g., redness, itching, stinging or burning, peeling and dryness) as a common cause for a patients’ dissatisfaction and/or lack of adherence.3,5 Topical calcineurin inhibitors and the only currently available topical phosphodiesterase- 4 inhibitor in Canada, are indicated for atopic dermatitis, but have been used for PsO with some success in the sensitive intertriginous and facial areas.6 There is limited access for these latter drugs depending on patients’ private insurance coverage.

PsO is a heterogeneous disease with varied clinical presentations with almost 90% of patients experiencing PsO in more than one location.4,6 Due to the limitations of today’s topical armamentarium, dermatologists often need to prescribe during one patient visit 2 or 3 different topicals of varying potencies and/or formulations. This can be troublesome for patients as they tend to forget or misunderstood the instructions provided by their dermatologist which can be confounded by further troubling instructions from the dispensing pharmacist.3,4 As such, the trouble with topicals today remains and there continues a large unmet need to develop a simplified regimen that is better tolerated with a cosmetically pleasing formulation which is steroid-sparing yet has a fast onset of action with an effectiveness comparable to mid-high potency TCSs. The trek towards this goal will be explored as new developments in topical non-steroid therapy will be presented.

Real-world evidence for dupilumab in atopic dermatitis

Insights into long-term, real-world treatment patterns for AD provide valuable information on current clinical practice and may lead to improvements in clinical decision-making. This presentation will provide an overview of the real-world data on dupilumab’s efficacy and safety from various RWE sources, including registry data base on COVID-19 in AD patients.

Objective:

Review the latest real-world evidence of Dupilumab in atopic dermatitis (AD)

Rapid Fire Lunch

New cosmetic procedure trends

Product Ingredient Update

Review contact dermatitis trends to personal care product ingredients, new allergens and industry product labelling changes.

Five Things to Know About Monkeypox

Questions & Answers

Treatment and maintenance of xerotic skin using a once-daily lipid-replenishing cleanser and moisturizer – an open-label, multicenter cohort study

In this session, Nicole Hawkins, MD, FRCPC, will review the results of this open-label, multicenter cohort study demonstrating that a once-daily lipid-replenishing skincare regimen was very well tolerated in subjects prone to skin irritation as well as significantly improved aesthetic signs of xerosis, including skin dryness.

I Can I Am: Reaching New Possibilities with the Canadian and American Clinical Experience with Tildrakizumab

Clinical trial data suggests what can be done (I Can), while clinical experience presents what is possible (I Am). Dr. Parbeer Grewal will provide an overview of what can be done, which will be followed by a panel discussion with Canadian dermatologist Dr. Vim Prajapati and American dermatologist Dr. George Han to understand what is possible based on real-world clinical experience with tildrakizumab through the presentation of patient cases. The session will conclude with an opportunity for the audience to pose questions to the panel.

Challenges in treating plaque psoriasis to target: special sites and managing inadequate response

Learning Objectives:

1. Review Canadian treat-to-target recommendations
2. Discuss considerations involved in applying treat-to-target principles and criteria to special sites
3. Review treatment modification strategies for patients with inadequate response to biologic treatments

Dermatology: Becoming a Procedurally Therapeutic Specialty Over 40 Years

Questions & Answers

Adjuvant Therapy for High-Risk Melanoma

More than 8000 patients receive the diagnosis of melanoma in Canada each year. Although most of these patients are cured with an excision, those with high-risk melanoma are at increased risk for distant metastasis and death. We will be reviewing current adjuvant treatment options for those patients and the emerging role of adjuvant immunotherapy.

Closing Comments

CaSMO Targeted Therapies Advisory Board

Boehringer Ingelheim Advisory Board